Phaseline

Companies › Good Molecules

Good Molecules: clinical trials, targets and expected readouts

3 active drug programs in 3 registered trials: 3 Phase 4; Other; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Investigational moisturizer
Topical moisturizer for skin barrier function
–Phase 4Sensitive SkinDec 2026
Chemical SPF 30
Chemical sunscreen (organic UV filters)
–Phase 4EpidermisFeb 2027
Hybrid D II SPF 30
Hybrid sunscreen (combination of organic and inorganic UV filters)
–Phase 4EpidermisFeb 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07811531Investigational moisturizerPhase 4Sensitive SkinOtherDec 2026
NCT07789639Hybrid D II SPF 30Phase 4EpidermisOtherFeb 2027
NCT07789639Chemical SPF 30Phase 4EpidermisOtherFeb 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Huons Biopharma Neuren Pharmaceuticals Tetra Discovery Partners Prove pharm Neuraptive Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.